183 related articles for article (PubMed ID: 12382089)
21. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
[TBL] [Abstract][Full Text] [Related]
22. [HIV infection: emerging issues and new challenges].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
[TBL] [Abstract][Full Text] [Related]
23. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
24. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
[TBL] [Abstract][Full Text] [Related]
25. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand.
Lee B; Aurpibul L; Sirisanthana V; Mangklabruks A; Sirisanthana T; Puthanakit T
HIV Med; 2009 Feb; 10(2):72-8. PubMed ID: 19018877
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
[TBL] [Abstract][Full Text] [Related]
27. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
28. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report.
Prasithsirikul W; Bunnag P
J Med Assoc Thai; 2004 Feb; 87(2):166-72. PubMed ID: 15061300
[TBL] [Abstract][Full Text] [Related]
29. What does the term "HIV-associated lipodystrophy" mean?
Marcason W
J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
[No Abstract] [Full Text] [Related]
30. Hypopituitarism and HIV-infection: a new comorbidity in the HAART era?
Zirilli L; Orlando G; Diazzi C; Squillace N; Carani C; Guaraldi G; Rochira V
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):33-8. PubMed ID: 19020383
[TBL] [Abstract][Full Text] [Related]
31. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
[TBL] [Abstract][Full Text] [Related]
32. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
Phillips DR; Hay P
J Antimicrob Chemother; 2008 Nov; 62(5):866-71. PubMed ID: 18703527
[TBL] [Abstract][Full Text] [Related]
33. Current perspectives on HIV-associated lipodystrophy syndrome.
Milinkovic A; Martinez E
J Antimicrob Chemother; 2005 Jul; 56(1):6-9. PubMed ID: 15905302
[TBL] [Abstract][Full Text] [Related]
34. Fat distribution in relation to drug use, human immunodeficiency virus (HIV) status, and the use of antiretroviral therapies in Hispanic patients with HIV infection.
Forrester JE; Gorbach SL
Clin Infect Dis; 2003; 37 Suppl 2():S62-8. PubMed ID: 12942376
[TBL] [Abstract][Full Text] [Related]
35. Cervical lipomatosis in HIV-infected patients: a case-control study.
Palacios R; Galindo MJ; Arranz JA; Lozano F; Estrada V; Rivero A; Morales D; Asensi V; del Arco A; Muñoz A; Santos J
HIV Med; 2007 Jan; 8(1):17-21. PubMed ID: 17305927
[TBL] [Abstract][Full Text] [Related]
36. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
37. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
38. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection.
Calza L; Masetti G; Piergentili B; Trapani F; Cascavilla A; Manfredi R; Colangeli V; Viale P
Int J STD AIDS; 2011 Jan; 22(1):43-5. PubMed ID: 21364066
[TBL] [Abstract][Full Text] [Related]
40. Lipodystrophy and metabolic complications of highly active antiretroviral therapy.
Parakh A; Dubey AP; Kumar A; Maheshwari A
Indian J Pediatr; 2009 Oct; 76(10):1017-21. PubMed ID: 19907933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
